Pasar al contenido principal

CONECTANDO EL METABOLISMO DE CELULAS MIELOIDES CON SU FUNCION

PID2022-137712OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics

  • Medina Hernández, Danielle
  • Cádiz Barrera, Laura
  • Mastrangelo, Annalaura
  • Moreno Arciniegas, Andrea
  • Fernández Tocino, Miguel
  • Cueto Becerra, Alejandro A.
  • Díaz-Guerra Priego, Anabel
  • Skoza, Warren A.
  • Higuero Verdejo, María Isabel
  • López Martín, Gonzalo Javier
  • Pérez Martínez, Claudia
  • Molina Iracheta, Antonio de
  • Caballero Valderrama, María
  • Sánchez González, Javier
  • Sancho Madrid, David
  • Fuster, Valentín
  • Galán Arriola, Carlos
  • Ibánez, Borja
[EN] Background: Anthracycline-induced cardiotoxicity (AIC) is characterized by a disruption in myocardial metabolism. Objectives: The authors used a large animal model to test sodium-glucose cotransporter inhibitor therapy to prevent AIC. Methods: Female large white pigs (n = 36) were used to identify the most translational AIC regimen: 6 triweekly intravenous doxorubicin injections (1.8 mg/kg each). Another group of 32 pigs were randomized (1:1:2) to doxorubicin plus empagliflozin 20 mg, doxorubicin plus empagliflozin 10 mg, or doxorubicin control. Pigs were serially examined using multiparametric cardiac magnetic resonance and magnetic resonance spectroscopy. At the end of the 21-week follow-up period, blood samples were obtained to measure myocardial metabolic substrate extraction, and the left ventricle was harvested and processed for analysis using metabolomics, transmission electron microscopy, mitochondrial respirometry, and histopathology. Results: Final left ventricular ejection fraction (LVEF), the prespecified primary outcome, was significantly higher in pigs receiving 20 mg empagliflozin than in the doxorubicin control group (median 57.5% [Q1-Q3: 55.5%-60.3%] vs 47.0% [Q1-Q3: 40.8%-47.8%]; P = 0.027). Final LVEF in pigs receiving 10 mg empagliflozin was 51% (Q1-Q3: 46.5%-55.5%; P = 0.020 vs 20 mg empagliflozin). The incidence of AIC events was 0%, 50%, and 72% in the empagliflozin 20 mg, empagliflozin 10 mg, and doxorubicin control groups, respectively. Empagliflozin 20 mg treatment resulted in enhanced ketone body consumption by the myocardium, preserved magnetic resonance spectroscopy–measured cardiac energetics, and improved mitochondrial structure and function on transmission electron microscopy and respirometry. These changes were more modest with the 10-mg empagliflozin dose. Conclusions: Sodium-glucose cotransporter-2 inhibitor therapy with empagliflozin exerts a dose-dependent cardioprotective effect against AIC. The improved LVEF was accompanied by enhanced ketone body consumption, improved cardiac energetics, and preserved mitochondrial structure and function, SI, This work was supported by the European Commission (ERC-CoG 819775 to Dr Ibáñez, and ERC-CoG 725091 to Dr Sancho), Spanish Ministry of Science, Innovation and Universities (PID2022-140176OBI00 to Dr Ibáñez, and PID2022-137712OB-I00 to Dr Sancho funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU), and the Red Madrileña de Nanomedicina en Imagen Molecular -Comunidad de Madrid (S2022/BMD-7403- RENIM-CM). Medina-Hernandez (ID LCF/ BQ/DI22/11940004), and Dr Skoza (ID LCF/BQ/DI23/11990056) are Doctoral INPhINIT Fellows from la Caixa Foundation (ID 100010434). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). Dr Sánchez-González is an employee of Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection

  • Hernández-García, Elena
  • Galán, Miguel
  • Khouili, Sofía C
  • Moya-Ruiz, Elena
  • Redondo-Urzainqui, Ana
  • Cueto, Francisco J
  • Martínez-Cano, Saraí
  • Rodrigo-Tapias, Manuel
  • Tomasello, Elena
  • Mañes, Santos
  • Dalod, Marc
  • Sancho, David
  • Iborra, Salvador
Resident memory CD8+ T cells (Trms) are essential for protecting barrier nonlymphoid tissues (NLTs) against reinfection, yet the involvement of dendritic cells (DCs) in this process and the nature of Trm-DC interactions within these tissues remain poorly understood. Our study demonstrates that upon reactivation, memory CD8+ T cells located in the skin-independently of circulating memory counterparts-initiate the infiltration and maturation of plasmacytoid DCs (pDCs) in the tissue. This, in turn, promotes the maturation of conventional type 1 DCs (cDC1s) through type I IFN (IFN-I) signaling in a pDC-dependent manner. Depletion of pDCs or blocking IFN-I signaling disrupts this axis, severely impairing Trm-driven protection against secondary infections with vaccinia virus (VACV) in the skin. Notably, this pDC-dependent, IFN-I-mediated pathway is also essential for Trm-mediated protection against secondary respiratory infections with influenza A virus (IAV). Our findings uncover a crucial collaboration between Trm, pDCs, and cDC1s, offering new insights for enhancing vaccines., Funder(s): Agencia Estatal de Investigación Award Id(s): PID2021-125415OB-I00 Funder(s): European Regional Development Fund Funder(s): Ministerio de Ciencia e Innovación Award Id(s): PID2022-137712OB-I00 , CPP2021-008310 , CPP2022-009762 , PID2023-147125OB-I00 Funder(s): Comunidad de Madrid Award Id(s): P2022/BMD-7333 INMUNOVAR-CM , PIPF-2022/SAL-GL-24581 , PIPF-2023/SAL-GL-29932 Funder(s): Centro Nacional de Investigaciones Cardiovasculares Funder(s): Scientific Foundation, Spanish Association Against Cancer Award Id(s): AECC-PRYGN246642SANC Funder(s): Worldwide Cancer Research Award Id(s): WWCR-25-0080 Funder(s): European Union Award Id(s): ERC-2023-PoC Funder(s): la Caixa Foundation Award Id(s): LCF/PR/HR23/52430012 , LCF/PR/HR22/52420019 Funder(s): Ministry of Science, Innovation, and Universities Award Id(s): CD21/00185 , PRE2019-087509 , FPU20/01418 , FPU16/03142 Funder(s): Instituto de Salud Carlos III Funder(s): Pro CNIC Foundation, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Imidazole propionate is a driver and therapeutic target in atherosclerosis

  • Mastrangelo, Annalaura
  • Robles-Vera, Iñaki
  • Mañanes, Diego
  • Galán, Miguel
  • Femenía-Muiña, Marcos
  • Redondo-Urzainqui, Ana
  • Barrero-Rodríguez, Rafael
  • Papaioannou, Eleftheria
  • Amores-Iniesta, Joaquín
  • Devesa, Ana
  • Lobo-González, Manuel
  • Carreras, Alba
  • Beck, Katharina R.
  • Ivarsson, Sophie
  • Gummesson, Anders
  • Georgiopoulos, Georgios
  • Rodrigo-Tapias, Manuel
  • Martínez-Cano, Sarai
  • Fernández-López, Ivan
  • Nuñez, Vanessa
  • Ferrarini, Alessia
  • Inohara, Naohiro
  • Stamatelopoulos, Kimon
  • Benguría, Alberto
  • Cibrian, Danay
  • Sánchez-Madrid, Francisco
  • Alonso-Herranz, Vanesa
  • Dopazo, Ana
  • Barbas, Coral
  • Vázquez, Jesús
  • López, Juan Antonio
  • González-Martín, Alicia
  • Nuñez, Gabriel
  • Stellos, Konstantinos
  • Bergström, Göran
  • Bäckhed, Fredrik
  • Fuster, Valentín
  • Ibañez, Borja
  • Sancho, David
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors1. However, individuals at risk for early vascular disease often remain unidentified2. Recent research has identified new molecules in the pathophysiology of atherosclerosis3, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we observed that imidazole propionate (ImP), produced by microorganisms, is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through the imidazoline-1 receptor (I1R, also known as nischarin) in myeloid cells. Blocking this ImP–I1R axis inhibited the development of atherosclerosis induced by ImP or high-cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis and the contribution of the ImP–I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis., M. O. Garmendia for assistance with the metadata from volunteers; members of the D.S. laboratory for help with discussions and critical reading of the manuscript; and the CNIC facilities, foremost the animal, cellomics, histology, metabolomics, genomics, microscopy, clinical trial and bioinformatics facilities, and personnel for assistance. I.R.-V. is funded by FJC2021-048099-I funded by MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. D.M. is funded by grant PRE2020-092578 MCIN/AEI/10.13039/501100011033. M.G. is funded by beca de formación de profesorado Universitario fellowship 20/01418. M.F.-M. is funded by INPhINIT Retaining 2024 from Caixa Foundation LCF/BQ/DR24/12080010. A.R.-U. is supported by Community of Madrid (PIPF-2022/SALGL-24581). R.B.-R. is funded by Beca de Formación de Profesorado Universitario Fellowship 20/03365. A. Devesa is scientifically supported by the Thrasher Research Fund and acknowledges the support of Sociedad Española de Cardiología (grant SEC/PRS-MOV-INT20/002). Work in the D.S. laboratory is funded by the CNIC; the European Union’s Horizon 2020 Research and Innovation Program under grant agreement ERC-2016-Consolidator Grant 725091; Ministerio de Ciencia, Innovación y Universidades (MICIU) PID2022-137712OB-I00, CPP2021-008310 and CPP2022-009762 MICIU/AEI/10.13039/501100011033 Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR; Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); Scientific Foundation of the Spanish Association Against Cancer (AECC- PRYGN246642SANC); Worldwide Cancer Research WWCR-25-0080; European Union ERC-2023-PoC; a research agreement with Inmunotek S.L.; and la Caixa Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). Work in the B.I. laboratory is supported by the European Commission (H2020-HEALTH 945118 and ERC-CoG 819775); the PID2022-140176OB-I00, PID2019-107332RB-I00 MCIN/AEI /10.13039/501100011033; and the Comunidad de Madrid RENIM P2022/BMD-7403. F.B. is funded by grants from the Swedish Heart Lung Foundation (20240882) and is a Wallenberg Fellow and recipient of an ERC-Advanced grant 2022 (101096705-IMPACT). K. Stellos was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation — Project ID 394046768 — SFB1366 ‘Vascular control of organ function’ C07), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (MODVASC, grant agreement 759248), the German Centre for Cardiovascular Research (DZHK) and the Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University, Heidelberg, Germany. Metabolomics Workbench is supported by NIH grant U2C-DK119886 and OT2-OD030544 grants. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033). The PESA study is funded by the CNIC and Santander Bank. This study was partially funded by an intramural grant CNIC-Severo Ochoa to B.I. and D.S., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade

  • Catena, Xavier
  • Contreras-Alcalde, Marta
  • Juan-Larrea, Naiara
  • Cerezo-Wallis, Daniela
  • Calvo, Tonantzin G.
  • Mucientes, Cynthia
  • Olmeda, David
  • Suárez, Javier
  • Oterino-Sogo, Sergio
  • Martínez, Lola
  • Megías, Diego
  • Sancho, David
  • Tejedo, Cristina
  • Frago, Susana
  • Dudziak, Diana
  • Seretis, Athanasios
  • Stoitzner, Patrizia
  • Soengas, María S.
Cutaneous melanomas express a high number of potential neoepitopes, yet a substantial fraction of melanomas shift into immunologically cold phenotypes. Using cellular systems, mouse models and large datasets, we identify the tumor-secreted growth factor midkine (MDK) as a multilayered inhibitor of antigen-presenting cells. Mechanistically, MDK acts systemically in primary tumors, lymph nodes and the bone marrow, promoting a STAT3-mediated impairment of differentiation, activation and function of dendritic cells (DCs), particularly, conventional type 1 DCs (cDC1s). Furthermore, MDK rewires DCs toward a tolerogenic state, impairing CD8+ T cell activation. Downregulating MDK improves DC-targeted vaccination, CD40 agonist treatment and immune checkpoint blockade in mouse models. Moreover, we present an MDK-associated signature in DCs that defines poor prognosis and immune checkpoint blockade resistance in individuals with cancer. An inverse correlation between MDK- and cDC1-associated signatures was observed in a variety of tumor types, broadening the therapeutic implications of MDK in immune-refractory malignancies., M.S.S. is funded by grants from the Ministerio de Ciencia e Innovación (project PID2020-117621RB-I00 and PID2023-147213OB-I00, funded by the Agencia Estatal de Investigación AEI/10.13039/501100011033), ‘La Caixa’ Banking Foundation under project codes HR17-00232 and HR20-00465 and the European Research Council through the advanced grant METALERT-STOP (grant agreement 884699, EU-Horizon 2020 Programme). D.O. is funded by grants from the Instituto de Salud Carlos III, AES-2021, through the project PI21/00641, which is cofunded by the European Fund FEDER. X.C., M.C.-A. and A.S. were funded by the Immutrain Marie Skłodowska-Curie ITN Grant (grant agreement 641549, EU-Horizon 2020 Programme). D.D. was funded by the German Research Foundation TRR305-TPB5 429280966 and DU548/9-1 515982377. D.S. is funded by MCIN PID2022-137712OB-I00 MCIN/AEI/10.13039/501100011033 European Union NextGeneration EU/PRTR and by ‘la Caixa’ Foundation (LCF/PR/HR23/52430012)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial complex I activity promotes antigen cross-presentation in dendritic cells

  • Khouili, Sofía C
  • Priego, Elena
  • Heras-Murillo, Ignacio
  • Dunphy, Gillian
  • Mastrangelo, Annalaura
  • Martínez-Cano, Sarai
  • Nuñez, Vanessa
  • Rodrigo-Tapias, Manuel
  • Belinchón-García, Adrián
  • Garaude, Johan
  • Iborra, Salvador
  • Chandel, Navdeep S
  • González-Rodríguez, Patricia
  • Enamorado, Michel
  • Sancho, David
[Data, Code, and Materials Availability] Sequencing data have been deposited in GEO under accession number GSE325287. Metabolomics data have been deposited in Metabolomics Workbench under accession number ST004768. Tabulated data underlying the figures are provided in data file S1, and uncropped immunoblots are provided in data file S2. All other data needed to support the conclusions of the paper are present in the paper or the Supplementary Materials. No custom code was generated. All materials are commercially available as described in Materials and Methods., Mitochondrial metabolism modulates immune cell signaling, yet how individual electron transport chain complexes fine-tune dendritic cell (DC) function remains unclear. Here, we identify mitochondrial complex I (CI) as a critical metabolic checkpoint controlling antigen cross-presentation by DCs in mice. Deficiency of the CI subunit NDUFS4 in DCs led to the formation of a nonfunctional CI subcomplex, resulting in mildly impaired mitochondrial respiration without triggering a compensatory glycolytic shift. NDUFS4 deficiency limited endosomal escape of internalized antigens, thereby impairing antigen cross-presentation while largely preserving direct presentation. CI dysfunction lowered the NAD+/NADH ratio, concomitant with decreased ATP levels, and diminished neutral lipid storage and lipid peroxidation. Restoration of the NAD+/NADH ratio rescued cross-presentation in NDUFS4-deficient DCs. NDUFS2-deficient DCs showed similar defects in cross-presentation, which were also rescued by rebalancing the NAD+/NADH ratio. Together, these findings reveal a link between mitochondrial CI integrity, NAD+-driven redox metabolism, and antigen cross-presentation., [Editor's summary] Cross-presentation of extracellular antigens by dendritic cells (DCs) is a specialized function critical for eliciting CD8 T cell responses against viral and tumor antigens. Khouili et al. show that mitochondrial complex I (CI) activity supports antigen endosomal escape and promotes efficient cross-presentation by conventional type 1 DCs (cDC1s). CI activity selectively in cDC1s was also necessary for optimal cross-priming of CD8 T cell responses during viral infection and tumor challenge. Loss of the CI subunit NDUFS4 or NDUFS2 disrupted DC redox homeostasis, whereas restoration of the NAD+/NADH ratio was sufficient to rescue cross-presentation capacity. These findings identify mitochondrial redox metabolism as a key regulator of antigen cross-presentation in DCs. —Claire Olingy, E.P. was funded by Contratos Predoctorales para la Formación de Doctores 2017 (Referencia: BES-2017-079717). Metabolomics Workbench (68) is supported by NIH grants U2C-DK119886 and OT2-OD030544. Work in the D.S. laboratory is funded by the CNIC; by Ministerio de Ciencia, Innovación y Universidades (MICIU) PID2022-137712OB-I00, PDC2025-165319-I00, CPP2022-009762, and CPP2024-011365 MICIU/AEI/10.13039/501100011033 Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR; by the Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); by the Scientific Foundation of the Spanish Association Against Cancer (AECC- PRYGN246642SANC); by the Worldwide Cancer Research WWCR-25-0080; by CRIS Foundation (excellence2025_03); and the by “la Caixa” Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). Work in M.E.’s Laboratory is supported by a seed package from the Icahn School of Medicine at Mount Sinai (Sinai Cloud Fund #IS127201039). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A type I interferon-mitochondrial axis regulates efferocytosis and interferon-stimulated gene induction in macrophages

  • Dunphy, Gillian
  • Adán-Barrientos, Irene
  • Fernández-Delgado, Irene
  • Villarroya-Beltri, Carolina
  • Heras-Murillo, Ignacio
  • Moya-Ruiz, Elena
  • Sánchez-Álvarez, Miguel
  • Jarit-Cabanillas, Aitor
  • del Pozo, Miguel A.
  • Guerra, Susana
  • Sánchez-Madrid, Francisco
  • Sancho, David
Macrophage metabolism is intricately linked to cellular function. Contrasting with Toll-like receptor (TLR) stimulation, cytosolic nucleic acid sensing induced a decrease in mitochondrial membrane potential (MMP) while maintaining mitochondrial respiration. Interferon α/β (IFN-I) receptor (IFNAR) signaling was necessary and sufficient for this metabolic response. IFNAR signaling induced interferon-stimulated gene 15 (ISG15) expression and ISGylation of mitochondrial proteins, including subunits of mitochondrial complex V, increasing ATP production and decreasing MMP, thus enhancing macrophage efferocytic capacity. Moreover, the IFNAR-ISG15-mediated drop in MMP activated the mitochondrial protease OMA1, inducing mitochondrial fission and decreasing endoplasmic reticulum-mitochondria communication, thus dampening IFN-stimulated gene (ISG) induction. Loss of ISG15 or OMA1 enhanced histone acetylation and ISG induction upon IFN-I stimulation, in a manner dependent on mitochondrial calcium uptake. This increase in ISG induction provided protection against acute viral infections. These data indicate that IFNAR-ISG15 signaling boosts efferocytosis while limiting ISG induction, thereby promoting the resolution of inflammation., The D.S. laboratory received support from the CNIC; the Ministerio de Ciencia, Innovación y Universidades (MICIU) (PID2022-137712OB-I00, CPP2021-008310, CPP2022-009762, and CPP2024-011365); MICIU/AEI/10.13039/501100011033 Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR; Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); the Scientific Foundation of the Spanish Association Against Cancer (AECC-PRYGN246642SANC); Worldwide Cancer Research (WWCR-25-0080); Fundación CRIS contra el cáncer (excellence2025_03); the European Union (ERC-2023-PoC GA-101158245-ImnovAth); and the “La Caixa” Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). M.A.d.P. acknowledges support from the Spanish Ministry of Science, Innovation & Universities (MICIU)/Agencia Estatal de Investigación (AEI)/FEDER (PID2023-146414OB-I00/AEI/10.13039/501100011033); from ERDF/EU; and from the Comunidad de Madrid (TecNanoBio-CM, ref. TEC-2024/TEC-158). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 892965. G.D. is supported by a European Molecular Biology Organization Long-term Fellowship ALTF 379-2019. I.A.-B. is supported by a Beca de Formación del Profesorado Universitario (FPU) fellowship (FPU18/05752). I.H.-M. is supported by a La Caixa INPhINIT fellowship (ID 100010434, fellowship code: LCF/BQ/IN17/11620074). E.M.-R. is a recipient of support from the Comunidad Autonoma de Madrid (PIPF-2023/SAL-GL-29932). A.J.-C. is supported by a Beca de Formación del Profesorado Universitario (FPU) fellowship (FPU18/05434). M.S.-A. is supported by the MICIU (RYC2020-029690-I and PID2021-128106NA-I00). Flow cytometry was conducted at the CNIC Flow Cytometry Unit. Microscopy was conducted at Microscopy & Dynamic Imaging, CNIC. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033).